PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

@article{Wu2010PI3KAktmTORPI,
  title={PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.},
  author={Peng Wu and Xiaojun Hu},
  journal={Current medicinal chemistry},
  year={2010},
  volume={17 35},
  pages={
          4326-41
        }
}
The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also known as protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital transduction cascade that is connected with many essential cellular activities, such as growth and survival. Along with extensive pharmacological studies validating the therapeutic potential of targeting the PI3K/Akt/mTOR pathway for the treatment of cancer, kinase inhibitors targeting significant knots of this pathway including… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…